84 related articles for article (PubMed ID: 9160695)
1. Use of partially mismatched related donors extends access to allogeneic marrow transplant.
Henslee-Downey PJ; Abhyankar SH; Parrish RS; Pati AR; Godder KT; Neglia WJ; Goon-Johnson KS; Geier SS; Lee CG; Gee AP
Blood; 1997 May; 89(10):3864-72. PubMed ID: 9160695
[TBL] [Abstract][Full Text] [Related]
2. Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia.
DeZern AE; Zahurak M; Symons H; Cooke K; Jones RJ; Brodsky RA
Biol Blood Marrow Transplant; 2017 Mar; 23(3):498-504. PubMed ID: 28013015
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.
Holtick U; Albrecht M; Chemnitz JM; Theurich S; Skoetz N; Scheid C; von Bergwelt-Baildon M
Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD010189. PubMed ID: 24748537
[TBL] [Abstract][Full Text] [Related]
4. Feasibility and safety of peripheral blood stem cell transplantation from unrelated donors: results of a single-center study.
Blau IW; Basara N; Lentini G; Guenzelmann S; Kirsten D; Schmetzer B; Bischoff M; Roemer E; Kiehl MG; Fauser AA
Bone Marrow Transplant; 2001 Jan; 27(1):27-33. PubMed ID: 11244435
[TBL] [Abstract][Full Text] [Related]
5. Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial.
DeZern AE; Eapen M; Wu J; Talano JA; Solh M; Dávila Saldaña BJ; Karanes C; Horwitz ME; Mallhi K; Arai S; Farhadfar N; Hexner E; Westervelt P; Antin JH; Deeg HJ; Leifer E; Brodsky RA; Logan BR; Horowitz MM; Jones RJ; Pulsipher MA
Lancet Haematol; 2022 Sep; 9(9):e660-e669. PubMed ID: 35907408
[TBL] [Abstract][Full Text] [Related]
6. Haploidentical Donor Bone Marrow Transplantation for Severe Aplastic Anemia.
DeZern AE; Brodsky RA
Hematol Oncol Clin North Am; 2018 Aug; 32(4):629-642. PubMed ID: 30047416
[TBL] [Abstract][Full Text] [Related]
7. Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia.
DeZern AE; Zahurak M; Symons HJ; Cooke KR; Huff CA; Jain T; Swinnen LJ; Imus PH; Wagner-Johnston ND; Ambinder RF; Levis M; Luznik L; Bolaños-Meade J; Fuchs EJ; Jones RJ; Brodsky RA
Blood; 2023 Jun; 141(25):3031-3038. PubMed ID: 37084383
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study.
Durand CM; Capoferri AA; Redd AD; Zahurak M; Rosenbloom DIS; Cash A; Avery RK; Bolaños-Meade J; Bollard CM; Bullen CK; Flexner C; Fuchs EJ; Gallant J; Gladstone DE; Gocke CD; Jones RJ; Kasamon YL; Lai J; Levis M; Luznik L; Marr KA; McHugh HL; Mehta Steinke S; Pham P; Pohlmeyer C; Pratz K; Shoham S; Wagner-Johnston N; Xu D; Siliciano JD; Quinn TC; Siliciano RF; Ambinder RF
Lancet HIV; 2020 Sep; 7(9):e602-e610. PubMed ID: 32649866
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors.
Rizzieri DA; Crout C; Storms R; Golob J; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Lagoo AS; Morris A; Beaven A; Yang Y; Peterson B; Li Z; Chao NJ
Cancer Invest; 2011 Jan; 29(1):56-61. PubMed ID: 21166499
[TBL] [Abstract][Full Text] [Related]
10. Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial.
Fuchs EJ; O'Donnell PV; Eapen M; Logan B; Antin JH; Dawson P; Devine S; Horowitz MM; Horwitz ME; Karanes C; Leifer E; Magenau JM; McGuirk JP; Morris LE; Rezvani AR; Jones RJ; Brunstein CG
Blood; 2021 Jan; 137(3):420-428. PubMed ID: 33475736
[TBL] [Abstract][Full Text] [Related]
11. Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia.
Eapen M; Le Rademacher J; Antin JH; Champlin RE; Carreras J; Fay J; Passweg JR; Tolar J; Horowitz MM; Marsh JC; Deeg HJ
Blood; 2011 Sep; 118(9):2618-21. PubMed ID: 21677312
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials.
Stem Cell Trialists' Collaborative Group
J Clin Oncol; 2005 Aug; 23(22):5074-87. PubMed ID: 16051954
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study.
Krishnamurti L; Neuberg DS; Sullivan KM; Kamani NR; Abraham A; Campigotto F; Zhang W; Dahdoul T; De Castro L; Parikh S; Bakshi N; Haight A; Hassell KL; Loving R; Rosenthal J; Smith SL; Smith W; Spearman M; Stevenson K; Wu CJ; Wiedl C; Waller EK; Walters MC
Am J Hematol; 2019 Apr; 94(4):446-454. PubMed ID: 30637784
[TBL] [Abstract][Full Text] [Related]
14. Severe, life-threatening, and fatal chronic health conditions after allogeneic blood or marrow transplantation in childhood.
Holmqvist AS; Chen Y; Hageman L; Landier W; Wu J; Francisco LF; Ross ES; Balas NA; Bosworth A; Te HS; Goldman FD; Rosenthal J; Wong FL; Weisdorf DJ; Armenian SH; Bhatia S
Cancer; 2023 Feb; 129(4):624-633. PubMed ID: 36484292
[TBL] [Abstract][Full Text] [Related]
15. HLA Class I Allele Loss and Bone Marrow Transplantation Outcomes in Immune Aplastic Anemia.
Zaimoku Y; Katagiri T; Nakagawa N; Imi T; Maruyama H; Takamatsu H; Ishiyama K; Yamazaki H; Miyamoto T; Nakao S
Transplant Cell Ther; 2024 Mar; 30(3):281.e1-281.e13. PubMed ID: 37972732
[TBL] [Abstract][Full Text] [Related]
16. Comparative Analysis of Allogeneic Bone Marrow Transplantation Outcomes Between Japanese and Non-Japanese Populations.
Yanagisawa R; Shindo M; Shinohara A; Kuwatsuka Y; Nakase K; Kimura F; Shingai N; Nishida T; Fukuda T; Sakurai M; Kurokawa M; Koike T; Ota S; Takada S; Onizuka M; Uchida N; Tanaka M; Noguchi M; Maruyama Y; Hagihara M; Ichinohe T; Atsuta Y; Kanda J; Nakasone H; Toubai T
Transplant Proc; 2024 Mar; 56(2):416-421. PubMed ID: 38336483
[TBL] [Abstract][Full Text] [Related]
17. "Is this the GVHD?" A qualitative exploration of quality of life issues in individuals with graft-versus-host disease following allogeneic stem cell transplant and their experiences of a specialist multidisciplinary bone marrow transplant service.
de Vere Hunt I; Kilgour JM; Danby R; Peniket A; Matin RN
Health Qual Life Outcomes; 2021 Jan; 19(1):11. PubMed ID: 33413414
[TBL] [Abstract][Full Text] [Related]
18. Minor histocompatibility antigens on transfused leukoreduced units of red blood cells induce bone marrow transplant rejection in a mouse model.
Desmarets M; Cadwell CM; Peterson KR; Neades R; Zimring JC
Blood; 2009 Sep; 114(11):2315-22. PubMed ID: 19525479
[TBL] [Abstract][Full Text] [Related]
19. Malignant Neoplasms of the Gastrointestinal Tract After Blood or Marrow Transplant.
McDonald A; Dai C; Meng Q; Hageman L; Richman J; Wu J; Francisco L; Ross E; Balas N; Bosworth A; Te HS; Wong FL; Landier W; Salzman D; Bhatia R; Weisdorf DJ; Forman SJ; Armenian SH; Bhatia S
JAMA Oncol; 2023 Mar; 9(3):376-385. PubMed ID: 36656600
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
